Health & bio

Eli Lilly acquires CrossBridge Bio for $300M on April 14

Houston-based ADC oncology startup accelerates Lilly's antibody-drug conjugate portfolio expansion.

Primary sources · 1
BioPharma Dive
← View the full 2026-04-09 (Thu) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →